focus -WSS

focus

author：focus 2025-08-23 08:56:42 - browse：91941

A sign of Elevance Health behind some flowers — coverage from STAT — Michael Conroy/AP

These days, the surefire way to get ahead in health insurance is to become a health care provider, and Elevance just upped the ante. It’s joining with private equity to launch a $4 billion primary care company.

Elevance leaders divulged more about the company’s venture with Clayton, Dubilier & Rice on its first quarter earnings call Thursday. The partners announced the new company, yet unnamed, earlier this week, but the release was light on detail. The strategic partnership will house Elevance and CD&R’s doctors, clinics, and the technologies that help those doctors manage their patients.

Health insurers specialize in managing medical costs, and through ventures like this, they apply that expertise to managing patients’ chronic medical conditions. In arrangements like Medicare Advantage, where insurers are paid set amounts for members’ care, they’re incentivized to keep those patients healthy.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the financial innards of our health care system — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： Stem cell biologist probes earliest stages of human development

WSS

Change Healthcare: What is it, why does its cyberattack matter?

The nurse manager staffing crisis is hurting patients

Longer MASH drug regimen improved liver, Akero study finds

DeSantis can now import cheaper drugs. But will Biden get credit?

$1 billion proposal to grow Boston, Massachusetts biotech

$1 billion proposal to grow Boston, Massachusetts biotech

Wikipedia

focus

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the financial innards of our health care system — by subscribing to STAT+.

leisure time

Malaria cases in Florida and Texas: Here’s what you need to know

Three issues to watch in global health in 2024

Psychedelics group wrestles with new pharma identity

First over

Guidelines to prevent youth baseball injuries need more muscle

State of the Union pitch: Bigger Medicare drug price negotiations

Drug repurposing or repositioning? The language matters

Readout LOUD podcast: 2023 in review, and a look at biotech in 2024

At least 13 dead in Texas as scorching temps continue

Three issues to watch in global health in 2024

entertainment

Readout LOUD podcast: FTC v. biotech, future of Pfizer and Vertex

DeSantis can now import cheaper drugs. But will Biden get credit?

Health and fitness trackers are measuring the wrong things

The public health thinking behind the CDC’s new Covid guidance

Heart disease and mental health: A look at cardiac psychology

Fetal cell organoids grown from amniotic fluid, study finds

focus

entertainment

leisure time

knowledge